Aim To conduct a meta‐analysis of randomized clinical trials (RCTs) to investigate whether
there is an association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first
introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and …

Obesity is a complex metabolic condition that can have a negative impact on one's health
and even result in mortality. The management of obesity has been addressed in a number of …

(1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for the
treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective study aimed at …

Background The emergence of genetically-modified human proteins and glucagon-like
peptide-1 (GLP-1) receptor agonists have presented a promising strategy for effectively …

Aim To assess whether oral semaglutide provides better glycaemic control, compared with
dipeptidyl peptidase‐4 inhibitor (DPP‐4i) continuation, in people with type 2 diabetes …

The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically
semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to …

From clinical trials and observational data, oral semaglutide has proven to be the most
effective second-line oral therapy for the management of patients with type 2 diabetes. This …

T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and
death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering
medications with salient benefits for body weight and cardiovascular events. This class of …